You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

CLINICAL TRIALS PROFILE FOR MIGLUSTAT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for MIGLUSTAT

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00194649 ↗ Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2) Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 4 2005-06-01 The purpose of this research study is to help in the development of safe, effective and reversible male contraception. We are examining the impact of the drug Miglustat on sperm production in normal men. We want to see if Miglustat will inhibit sperm production in men and act as a reversible male contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of sperm production. We believe Miglustat may have some potential as a safe, reversible male contraceptive.
NCT00194649 ↗ Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2) Completed University of Washington Phase 4 2005-06-01 The purpose of this research study is to help in the development of safe, effective and reversible male contraception. We are examining the impact of the drug Miglustat on sperm production in normal men. We want to see if Miglustat will inhibit sperm production in men and act as a reversible male contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of sperm production. We believe Miglustat may have some potential as a safe, reversible male contraceptive.
NCT00319046 ↗ Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease Completed Actelion Phase 3 2006-02-01 Although miglustat has been approved as a treatment for mild to moderate type 1 Gaucher disease in patients who are unsuitable for enzyme replacement therapy (ERT), more data are required to establish the long term efficacy, safety and tolerability of miglustat in maintaining diseases stability after a switch from ERT.
NCT00418847 ↗ Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis Completed Actelion Phase 2 2004-07-01 The purpose of the study is to investigate the pharmacokinetics of Zavesca (miglustat, OGT918) when given as single and multiple doses in juvenile patients with GM2 gangliosidosis.
NCT00418847 ↗ Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis Completed The Hospital for Sick Children Phase 2 2004-07-01 The purpose of the study is to investigate the pharmacokinetics of Zavesca (miglustat, OGT918) when given as single and multiple doses in juvenile patients with GM2 gangliosidosis.
NCT00517153 ↗ Miglustat in Niemann-Pick Type C Disease Completed Actelion Phase 2 2002-01-01 This is a phase II randomized controlled study of miglustat in adult and juvenile patients with Niemann-Pick Type C disease. Up to 42 patients will be randomised in a 2:1 ratio to either treatment with miglustat or to a non-treatment group. Both groups will follow an identical visit schedule.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for MIGLUSTAT

Condition Name

Condition Name for MIGLUSTAT
Intervention Trials
Cystic Fibrosis 4
Niemann-Pick Disease, Type C 3
Pompe Disease 3
Pompe Disease (Late-onset) 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for MIGLUSTAT
Intervention Trials
Glycogen Storage Disease Type II 7
Niemann-Pick Diseases 7
Niemann-Pick Disease, Type C 7
Niemann-Pick Disease, Type A 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for MIGLUSTAT

Trials by Country

Trials by Country for MIGLUSTAT
Location Trials
United States 72
Australia 10
Canada 8
Germany 7
United Kingdom 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for MIGLUSTAT
Location Trials
Florida 7
California 7
Virginia 5
Pennsylvania 5
North Carolina 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for MIGLUSTAT

Clinical Trial Phase

Clinical Trial Phase for MIGLUSTAT
Clinical Trial Phase Trials
Phase 4 3
Phase 3 9
Phase 2/Phase 3 2
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for MIGLUSTAT
Clinical Trial Phase Trials
Completed 14
Recruiting 5
Active, not recruiting 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MIGLUSTAT

Sponsor Name

Sponsor Name for MIGLUSTAT
Sponsor Trials
Actelion 10
Amicus Therapeutics 6
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for MIGLUSTAT
Sponsor Trials
Other 24
Industry 21
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.